Abstract 477P
Background
Lower grade gliomas (LGGs) represent 15% of all primary brain tumors, and have variable prognosis. The prognostic influence of the ENHO gene in LGGs remains elusive, necessitating further bioinformatic exploration to improve patient management and outcomes.
Methods
Differential gene expression based on High/low ENHO expression was extracted using the “DESeq2” R package. Immune infiltration, mutational burden, gene set variation analysis (GSVA) and drug resistance were analyzed through GSCALite and cBioPortal. Additional immune infiltration and survival analysis used TIMER2.0. Gene set enrichment analysis (GSEA) was conducted via TCGAbiolinks and enriched further using Enrichr.
Results
Multivariate overall survival (OS) analysis showed a protective effect for ENHO (HR = 0.58, p <0.001). GSVA for OS and progression-free survival (PFS) for co-expressed genes and upregulated genes also showcased favorable prognosis OS:(HR = 0.40, p<0.001) and (HR = 0.34, p<0.001), respectively; PFS: (HR = 0.53, p<0.001) and (HR = 0.44, p<0.001), respectively. Survival GSVA of downregulated genes revealed an association with worse OS (HR = 4.19, p < 0.001) and PFS (HR = 2.45, p< 0.001). GSVA for upregulated genes showed a negative correlation with DNA damage, EMT, and PI3KAKT pathways. GSVA for downregulated genes had a positive correlation with EMT, DNA damage, and PI3K/AKT pathways. GSVA for co-expressed genes revealed significant negative correlations with DNA damage and EMT pathways. Mutational burden analysis revealed that shallow deletion is the most common ENHO mutation among all LGG subtypes, regardless of stage. Immune infiltration analysis for ENHO, upregulated, and co-expressed genes showcased the infiltration of: Central memory B cells, CD8 T cells, Neutrophils, and CD4 T cells. Decreased infiltration of cancer associated fibroblasts was observed for high ENHO expression. GSEA of coexpressed genes revealed significant involvement in cell cycle processes and regulation.
Conclusions
ENHO's role in LGG is yet to be determined, but our results showcase a possible protective effect through its modulation of the immune system, cell cycle signalling, and EMT pathways. Primary studies are still needed to validate ENHO's role in LGG.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
489P - Interfering with the tumor microenvironment of glioblastoma: An in vitro study
Presenter: Serena Mastantuono
Session: Poster session 16
490P - Inhibiting glioma cells' migration: Exploring Rho-GTPases as a potential therapeutic target
Presenter: Irene Giulia Rolle
Session: Poster session 16
Resources:
Abstract
491P - SRSF7 promotes glioblastoma progression via CDK1-mediated G2/M phase arrest of GBM cells
Presenter: Ya qin Hu
Session: Poster session 16
Resources:
Abstract
492P - Linking cellular drug responses to corresponding metabolomic tissue signatures in gliomas
Presenter: Stefanie Stanzer
Session: Poster session 16
493P - The usefulness of pre-radiotherapy MRI in assessing pseudo-progression in patients with glioblastoma included in first-line clinical trials
Presenter: Kreina Vega Cano
Session: Poster session 16
494P - Effect of a new method for operating electric field patches on scalp reactions in glioblastoma patients receiving tumor treating fields
Presenter: Jinghui Liu
Session: Poster session 16
Resources:
Abstract
495P - Clinicopathological risk factors for prognosis and therapeutic response of primary central nervous system lymphoma in China: A single-center retrospective analysis of 118 cases
Presenter: Feng Chen
Session: Poster session 16
496P - Association of brain metastasis and peritumoral edema volume with the neurological symptom burden in lung cancer patients
Presenter: Ariane Steindl
Session: Poster session 16
497P - Does the primary location and metastatic timing of colorectal cancer influence the survival of patients with brain metastasis? A meta-analysis
Presenter: Junmin Song
Session: Poster session 16